These mutations increase the susceptibility to EGFR-TKIs activity [5,6] but all the EGFR-mutant lung cancer patients experience disease progression within 10 to 14 months from the beginning of the therapy [7–9]. The gene discussed is EGFR; the disease is lung carcinoma.